AS
Anilkumar Shridhar Mulye
About Anilkumar Shridhar Mulye
Data last updated:
Anilkumar Shridhar Mulye is a Director at Enem Nostrum Remedies Private Limited (since 2024), Director at Nli Healthcare (India) Private Limited (since 2024) and Director at Nexgen Healthcare Private Limited (since 2024), and holds 6 more current directorships. The companies operate in Pharma, Information Technology and Life Sciences. The 8 current companies with reported revenue have a combined latest revenue of ₹43.05 Cr; the largest is Enem Nostrum Remedies Private Limited at ₹42.33 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 16 Sep 2024 | 2001 | ₹42.33 Cr (FY 2025) | Active | |
| Director | 16 Sep 2024 | 2019 | ₹58.9 Lakh (FY 2024) | Active | |
| Director | 11 Sep 2024 | 2004 | ₹6.3 Lakh (FY 2025) | Active | |
| Director | 11 Sep 2024 | 2007 | ₹5.5 Lakh (FY 2025) | Active | |
| Director | 16 Sep 2024 | 2011 | ₹35,170 (FY 2023) | Active | |
| Director | 16 Sep 2024 | 2007 | ₹21,450 (FY 2022) | Active | |
| Director | 11 Sep 2024 | 2000 | ₹20,120 (FY 2022) | Active | |
| Director | 11 Sep 2024 | 2012 | ₹15,350 (FY 2023) | Active |
Board colleagues of Anilkumar Shridhar Mulye
| Name | DIN | Company | Designation |
|---|---|---|---|
| Shraddha Vinayak Dhamankar | 00553157 | Enem Nostrum Remedies Private Limited , Nli Healthcare (India) Private Limited and 7 more | Director |
| Kaushik Krishnakant Vyas | 08642670 | Symmetrix Biotech Private Limited | Director |
| Rama Ravikiran Marathe | 05191501 | Symmetrix Biotech Private Limited | Director |
| Yatindra Prashar | 02673472 | Symmetrix Biotech Private Limited | Director |
| Nirmal Vasant Mulye | 01459942 | Bombay Bio-Research Centre Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Anilkumar Shridhar Mulye
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anilkumar Shridhar Mulye
Anilkumar Shridhar Mulye currently holds 9 directorships: Enem Nostrum Remedies Private Limited (Director, since 16 Sep 2024, revenue ₹42.33 Cr (FY 2025)); Nli Healthcare (India) Private Limited (Director, since 16 Sep 2024, revenue ₹58.9 Lakh (FY 2024)); Nexgen Healthcare Private Limited (Director, since 11 Sep 2024, revenue ₹6.3 Lakh (FY 2025)); Symmetrix Biotech Private Limited (Director, since 11 Sep 2024, revenue ₹5.5 Lakh (FY 2025)); Bombay Bio-Research Centre Private Limited (Director, since 16 Sep 2024, revenue ₹35,170 (FY 2023)); and 4 more.
Anilkumar Shridhar Mulye was first appointed on 11 Sep 2024 as Director at Nexgen Healthcare Private Limited.
The 8 current companies of Anilkumar Shridhar Mulye that report revenue have a combined latest revenue of ₹43.05 Cr: Enem Nostrum Remedies Private Limited ₹42.33 Cr (FY 2025); Nli Healthcare (India) Private Limited ₹58.9 Lakh (FY 2024); Nexgen Healthcare Private Limited ₹6.3 Lakh (FY 2025); Symmetrix Biotech Private Limited ₹5.5 Lakh (FY 2025); Bombay Bio-Research Centre Private Limited ₹35,170 (FY 2023); and 3 more.
The current boards of Anilkumar Shridhar Mulye's companies include Shraddha Vinayak Dhamankar (Enem Nostrum Remedies Private Limited), Kaushik Krishnakant Vyas (Symmetrix Biotech Private Limited), Rama Ravikiran Marathe (Symmetrix Biotech Private Limited), Yatindra Prashar (Symmetrix Biotech Private Limited), Nirmal Vasant Mulye (Bombay Bio-Research Centre Private Limited).